Back to News

6 of the Top 20 Global Pharmaceutical Companies Standardizing on ³Ô¹Ï±¬ÁÏ Vault QMS

More than 175 companies adopt Vault QMS to streamline end-to-end quality processes

PLEASANTON, CA ¡ª May 12, 2021 - Leading companies continue to prioritize the modernization of quality management. With this shift well underway, six of the top 20 global pharmaceutical companies have partnered with ³Ô¹Ï±¬ÁÏ Systems (NYSE: VEEV) to standardize on ³Ô¹Ï±¬ÁÏ Vault QMS for greater efficiency and better visibility across the enterprise. A growing number of organizations, including more than 175 biopharma, contract manufacturers, generics, and medtech companies, have adopted Vault QMS to streamline and automate quality processes.

¡°As a long-standing partner, ³Ô¹Ï±¬ÁÏ has been collaborating closely with us on our digital quality initiatives," said Nicol¨¢s Maldonado, senior director, quality policies and systems at Gilead Sciences. "We are excited to bring in ³Ô¹Ï±¬ÁÏ Vault QMS to simplify, harmonize, and automate quality processes across multiple strategic businesses within Gilead.¡±

More organizations are adopting ³Ô¹Ï±¬ÁÏ¡¯s modern cloud solutions to bring together quality processes for greater transparency and real-time visibility across global sites, manufacturing partners, and suppliers. Industry leaders are partnering with ³Ô¹Ï±¬ÁÏ to simplify quality management and increase operational efficiency with a unified quality platform.

¡°Companies want a trusted partner that remains focused on customer success for digital quality transformation,¡± said Mike Jovanis, vice president, ³Ô¹Ï±¬ÁÏ Vault Quality. ¡°³Ô¹Ï±¬ÁÏ is committed and will continue to deliver customer-focused innovation across product development and manufacturing.¡±

³Ô¹Ï±¬ÁÏ¡¯s continuous innovation is helping customers proactively manage quality and increase agility. Over the last year, new features for Vault QMS include:

  • Seamless connection between Vault QMS and ³Ô¹Ï±¬ÁÏ Vault Registrations to reduce cycle time and increase transparency within post-market change control
  • Quality Risk Management (QRM) advancements, including FMEA methodology to support proactive identification and mitigation of risks
  • Fully automated process for external auditees such as CMOs and suppliers to respond to audit findings directly within the system

Vault QMS is part of the ³Ô¹Ï±¬ÁÏ Vault Quality Suite, including ³Ô¹Ï±¬ÁÏ Vault QualityDocs, ³Ô¹Ï±¬ÁÏ Vault Training, ³Ô¹Ï±¬ÁÏ Vault Station Manager, and ³Ô¹Ï±¬ÁÏ Vault Product Surveillance to automate and harmonize quality processes globally.

In other news today, ³Ô¹Ï±¬ÁÏ announced that Bluepharma selected Vault Quality Suite to unify global quality management. Read the press release for more information.

Learn more about Vault Quality Suite at the upcoming ³Ô¹Ï±¬ÁÏ R&D and Quality Summit Connect Europe, 20 May 2021. The online event is open to life sciences industry professionals. Register and stay up to date on program details at veeva.com/Summit.

Additional Information
For more on ³Ô¹Ï±¬ÁÏ Vault QMS, visit: veeva.com/QMS
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
Follow @veevasystems on Twitter:

About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 975 customers, ranging from the world¡¯s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ¡¯s products and services, the results from use of ³Ô¹Ï±¬ÁÏ¡¯s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ¡¯s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ¡¯s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ¡¯s financial results are included under the captions, ¡°Risk Factors¡± and ¡°Management¡¯s Discussion and Analysis of Financial Condition and Results of Operations,¡± in the company¡¯s filing on Form 10-K for the period ended January 31, 2021. This is available on the company¡¯s website at veeva.com under the Investors section and on the SEC¡¯s website at . Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.

###

Contact:

Deivis Mercado
³Ô¹Ï±¬ÁÏ Systems
925-226-8821
deivis.mercado@veeva.com